IMMIX BIOPHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.12 USD | -3.64% |
|
+10.94% | -69.22% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 47.02 | 31.89 | 137.5 | 58.11 | - |
| Enterprise Value (EV) 1 | 47.02 | 18.46 | 120 | 46.12 | 72.57 |
| P/E ratio | -0.54 x | -3.88 x | -7.78 x | -2.37 x | -2.18 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | -2.25 x | -7.44 x | -2.1 x | -2.79 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,209 | 13,927 | 19,867 | 26,414 | - |
| Reference price 2 | 3.560 | 2.290 | 6.920 | 2.200 | 2.200 |
| Announcement Date | 28/03/22 | 27/03/23 | 29/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | - | -8.217 | -16.14 | -21.96 | -26.01 |
| EBIT 1 | - | -8.219 | -16.14 | -21.96 | -26.16 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -8.219 | -15.57 | -21.44 | -26.55 |
| Net income 1 | -24.38 | -8.23 | -15.43 | -21.47 | -26.59 |
| Net margin | - | - | - | - | - |
| EPS 2 | -6.640 | -0.5900 | -0.8900 | -0.9300 | -1.010 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 28/03/22 | 27/03/23 | 29/03/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -3.795 | -2.521 | -3.721 | -4.524 | -5.376 | -5.59 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.795 | -2.493 | -3.592 | -4.337 | -5.147 | -5.322 |
| Net income 1 | -1.535 | -3.8 | -2.48 | -3.576 | -4.281 | -5.09 | -5.259 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -0.1100 | -0.2700 | -0.1800 | -0.2400 | -0.2300 | -0.2400 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 09/11/22 | 27/03/23 | 12/05/23 | 11/08/23 | 13/11/23 | 29/03/24 | 09/05/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 14.5 |
| Net Cash position 1 | - | 13.4 | 17.5 | 12 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.5558 x |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.05 | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 28/03/22 | 27/03/23 | 29/03/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
0
Last Close Price
2.2
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -69.22% | 58.11M | |
| +2.97% | 94.74B | |
| -3.68% | 37.28B | |
| -11.57% | 32.68B | |
| +74.21% | 27.72B | |
| -13.91% | 16.19B | |
| -2.12% | 13.88B | |
| -12.21% | 11.58B | |
| +188.83% | 10.92B | |
| -53.94% | 9.54B |
- Stock Market
- Equities
- IMMX Stock
- Financials Immix Biopharma, Inc.
